Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 5:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2425–2448 of 18,757 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Phase I Clear all
Completed Phase 1 Interventional

Phase 1 of EC1169 In Patients With Recurrent MCRPC

NCT02202447
View directory record Official record
Conditions
Prostate Cancer
Interventions
EC1169, EC0652
Drug · Other
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Scottsdale, Arizona • New Haven, Connecticut • New Orleans, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Nov 13, 2026, 5:42 PM EST
Completed Phase 2 Interventional

Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma

NCT00030849
View directory record Official record
Conditions
Lymphoma
Interventions
recombinant interferon alfa, bexarotene
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
5
States / cities
Miami, Florida • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Nov 13, 2026, 5:42 PM EST
Completed Phase 1 Interventional

Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors

NCT01292655
View directory record Official record
Conditions
Cancer
Interventions
BMS-906024
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
6
States / cities
Los Angeles, California • Atlanta, Georgia • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Nov 13, 2026, 5:42 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

ZD03 Capsule Study

NCT04693455
View directory record Official record
Conditions
Healthy
Interventions
ZD03, Placebo
Drug · Other
Lead sponsor
Shanxi Zhendong Leading Biotechnology Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Nov 13, 2026, 5:42 PM EST
Recruiting Phase 1Phase 2 Interventional

Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

NCT06750185
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
BNT317 DL1, BNT317 DL2, BNT317 DL3, BNT317 DL4, BNT317 DL5, BNT317 DL6, BNT317 selected DLA, BNT317 selected DLB, SoC chemotherapy 1, SoC chemotherapy 2
Biological · Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
7
States / cities
Louisville, Kentucky • Grand Rapids, Michigan • Huntersville, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Nov 13, 2026, 5:42 PM EST
Completed Phase 1 Interventional Results available

Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

NCT03489343
View directory record Official record
Conditions
Metastatic Cancer, Solid Tumor, Lymphoma
Interventions
Sym023
Drug
Lead sponsor
Symphogen A/S
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Grand Rapids, Michigan • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Nov 13, 2026, 5:42 PM EST
Completed Phase 1 Interventional

Dose-Escalation Safety and Pharmacokinetic Study of Iso-Fludelone in Patients With Advanced Solid Tumors

NCT01379287
View directory record Official record
Conditions
Solid Tumors
Interventions
Iso-Fludelone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Nov 13, 2026, 5:42 PM EST
Enrolling by invitation No phase listed Observational

Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) Precision Medicine Phase 2 Option 1

NCT04602806
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
5
States / cities
San Francisco, California • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 13, 2026, 5:42 PM EST
Completed Phase 1Phase 2 Interventional

Phase I/II Combination With Irinotecan- Erbitux

NCT00594984
View directory record Official record
Conditions
Metastatic Colorectal Cancer (MCRC)
Interventions
Cetuximab, Irinotecan, Brivanib, Brivanib Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Louisville, Kentucky • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Nov 13, 2026, 5:42 PM EST
Terminated Phase 1 Interventional Accepts healthy volunteers

Study of the Effects of Itraconazole and Carbamazepine on LY3410738 in Healthy Participants

NCT05205447
View directory record Official record
Conditions
Healthy
Interventions
LY3410738, Itraconazole, Carbamazepine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Nov 13, 2026, 5:42 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult Participants

NCT06033547
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir Formulation F, Cabotegravir Formulation G
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Nov 13, 2026, 5:42 PM EST
Recruiting Phase 1 Interventional

TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly Glioma

NCT07862647
View directory record Official record
Conditions
Glioblastom WHO Grade 4, GBM, bGBM, Butterfly GBM, Bihemispheric GBM, Glioblastoma
Interventions
5-ALA, Porphyrin Metabolite Activation (PoMA) with LIDU ultrasound
Drug · Device
Lead sponsor
Alpheus Medical, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Nov 13, 2026, 5:42 PM EST
Active, not recruiting Phase 1 Interventional

IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM

NCT04003649
View directory record Official record
Conditions
Recurrent Glioblastoma, Refractory Glioblastoma
Interventions
IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells, Ipilimumab, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Nov 13, 2026, 5:42 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Rifampin on the Pharmacokinetics of BAY73-4506

NCT01322438
View directory record Official record
Conditions
Neoplasms
Interventions
Regorafenib (BAY73-4506) + rifampin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Nov 13, 2026, 5:42 PM EST
Withdrawn Phase 1 Interventional

ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck

NCT06357858
View directory record Official record
Conditions
Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions
INQOVI (decitabine and cedazuridine), Nivolumab
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Nov 13, 2026, 5:42 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

BIO 300 Oral Powder Safety and Pharmacokinetics

NCT04650555
View directory record Official record
Conditions
Acute Radiation Syndrome
Interventions
BIO 300 Oral Powder
Drug
Lead sponsor
Humanetics Corporation
Industry
Eligibility
18 Years to 64 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Nov 13, 2026, 5:42 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Single-Ascending-Dose Study of BT051 in Healthy Subjects

NCT05103878
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BT051 100mg, BT051 300mg, BT051 700mg, BT051 1500mg, BT051 3500mg, Matching Placebo
Drug
Lead sponsor
Bacainn Therapeutics, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Nov 13, 2026, 5:42 PM EST
Active, not recruiting Phase 1 Interventional

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

NCT04483778
View directory record Official record
Conditions
Pediatric Solid Tumor, Germ Cell Tumor, Retinoblastoma, Hepatoblastoma, Wilms Tumor, Rhabdoid Tumor, Carcinoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Synovial Sarcoma, Clear Cell Sarcoma, Malignant Peripheral Nerve Sheath Tumors, Desmoplastic Small Round Cell Tumor, Soft Tissue Sarcoma, Neuroblastoma, Melanoma
Interventions
second generation 4-1BBζ B7H3-EGFRt-DHFR, second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG, Pembrolizumab
Biological · Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
0 Years to 26 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2040
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Nov 13, 2026, 5:42 PM EST
Completed Phase 1 Interventional

Pharmacokinetics and Safety of Intravenous Topiramate in Adult Patients

NCT00753493
View directory record Official record
Conditions
Epilepsy, Migraines
Interventions
intravenous topiramate
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Nov 13, 2026, 5:42 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Needle Safety Device (PFS+NSD) in Healthy Participants

NCT03949621
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vedolizumab SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Nov 13, 2026, 5:42 PM EST
Terminated Phase 1 Interventional

Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide

NCT01200004
View directory record Official record
Conditions
Advanced Cancers
Interventions
Azacitidine, Lenalidomide, Grifola Frondosa
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
13 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Nov 13, 2026, 5:42 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and PK of Nikkomycin Z in Healthy Subjects

NCT00834184
View directory record Official record
Conditions
Healthy
Interventions
nikkomycin Z
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 40 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Nov 13, 2026, 5:42 PM EST
Withdrawn Phase 1Phase 2 Interventional

Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

NCT03973333
View directory record Official record
Conditions
Select Advanced Solid Tumors
Interventions
IMC-C103C, Atezolizumab
Drug
Lead sponsor
Immunocore Ltd
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
10
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2024 · Synced Nov 13, 2026, 5:42 PM EST
Completed Phase 1 Interventional

Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy

NCT04676633
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Metastases, Cholangiocarcinoma
Interventions
STP705
Drug
Lead sponsor
Sirnaomics
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Scottsdale, Arizona • Los Angeles, California • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Nov 13, 2026, 5:42 PM EST